Preventing blood clots in multiple myeloma: aspirin vs rivaroxaban
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial is testing whether aspirin or a blood thinner called rivaroxaban can best prevent harmful blood clots in people newly diagnosed with multiple myeloma who have a high risk of developing clots. It aims to find a safer and more effective way to protect you during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with multiple myeloma (a type of blood cancer).
- Your doctor has told you that you have a high risk of developing blood clots (VTE).
- You are between 18 and 90 years old.
- You are not pregnant or breastfeeding, and you do not have active bleeding or a stomach ulcer that is bleeding.
- You are not already taking blood thinners for other heart or blood vessel conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how blood thinners are used in people with newly diagnosed multiple myeloma. The goal is to find better ways to prevent blood clots during treatment.
This study looks at how Apixaban (a blood thinner) works in people with newly diagnosed multiple myeloma. It compares them to people having knee replacement surgery. The goal is to see if the drug prevents clots effectively in both groups.
This trial tests whether rivaroxaban, a blood thinner pill, can help prevent dangerous blood clots in people with certain genitourinary cancers who are starting cancer treatment. It may lower clot risk, but it also has bleeding-risk tradeoffs that the study will monitor closely.
This study looks at bleeding risks in people newly diagnosed with multiple myeloma who are taking blood thinners (aspirin or a low-molecular-weight heparin). You'll fill out a few questionnaires to help doctors learn how to better prevent bleeding.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
This trial tests whether a blood thinner called rivaroxaban (a pill) works well for older Chinese patients who have had a blood clot in their lungs and are now on long-term treatment. It aims to see if it's safe and effective for this group.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.